Combinatorial therapeutic activation with heparin and AICAR stimulates additive effects on utrophin A expression in dystrophic muscles

Human Molecular Genetics

Volumn 25, Issue 1, 2016, Pages 24-43

  Péladeau, Christine ^a   Ahmed, Aatika ^a   Amirouche, Adel ^a   Crawford Parks, Tara E ^a   Bronicki, Lucas M ^a   Ljubicic, Vladimir ^a   Renaud, Jean Marc ^a   Jasmin, Bernard J ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; BETA DYSTROGLYCAN; HEPARIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE; UNCLASSIFIED DRUG; UTROPHIN; UTROPHIN A; 5 AMINO 4 IMIDAZOLECARBOXAMIDE; AICA RIBONUCLEOTIDE; RIBONUCLEOTIDE; UTRN PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIAPHRAGM; EXTENSOR DIGITORUM LONGUS MUSCLE; MORPHOLOGY; MOUSE; MUSCULAR DYSTROPHY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOLEMMA; STIMULATION; TIBIALIS ANTERIOR MUSCLE; TRANSCRIPTION INITIATION; ANALOGS AND DERIVATIVES; ANIMAL; BIOSYNTHESIS; CELL LINE; COMBINATION DRUG THERAPY; DRUG EFFECTS; GENETICS; METABOLISM; MUSCULAR DYSTROPHY, DUCHENNE; PATHOLOGY; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; UPREGULATION; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

AMINOIMIDAZOLE CARBOXAMIDE; ANIMALS; CELL LINE; DRUG THERAPY, COMBINATION; HEPARIN; MICE; MICE, INBRED MDX; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RIBONUCLEOTIDES; SIGNAL TRANSDUCTION; UP-REGULATION; UTROPHIN;

EID: 84962150062     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddv444     Document Type: Article

References (121)

1. Emery, A.E.H. (1991) Population frequencies of inherited neuromuscular diseases-a world survey. Neuromuscul. Disord., 1, 19-29
2. Anderson, M.S. and Kunkel, L.M. (1992) The molecular and biochemical basis of Duchenne muscular dystrophy. Trends Biochem. Sci., 17, 289-292
3. Baxter, P. (2006) Treatment of the heart in Duchenne muscular dystrophy. Dev. Med. Child Neurol., 48, 163
4. Gayraud, J., Ramonatxo, M., Rivier, F., Humberclaude, V., Petrof, B. and Matecki, S. (2010) Ventilatory parameters and maximal respiratory pressure changes with age in Duchenne muscular dystrophy patients. Pediatr. Pulmonol., 45, 552-559
5. Ryan, T.D., Jefferies, J.L., Sawnani, H., Wong, B.L., Gardner, A., Del Corral, M., Lorts, A. and Morales, D.L.S. (2014) Implantation of the HeartMate II and HeartWare left ventricular assist devices in patients with Duchenne muscular dystrophy: lessons learned from the first applications. ASAIO J., 60, 246-248
6. Bushby, K., Finkel, R., Birnkrant, D.J., Case, L.E., Clemens, P. R., Cripe, L., Kaul, A., Kinnett, K., McDonald, C., Pandya, S. et al. (2010) Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol., 9, 77-93
7. Worton, R.G. and Thompson, M.W. (1988) Genetics of Duchenne muscular dystrophy. Annu. Rev. Genet., 22, 601-629
8. Straathof, C.S.M., Van Heusden, D., Elly, P., Ippel, F., Jan, G., Voermans, N.C., De Visser, M. and Brusse, E. (2015) Diagnosis of Becker muscular dystrophy: results of re-analysis of DNA samples. Muscle Nerve., [Epub ahead of print]
9. Nigro, V. and Piluso, G. (2015) Spectrum of muscular dystrophies associated with sarcolemmal-protein genetic defects. Biochim. Biophys., 1852, 585-593
10. Yang, B., Jung, D., Rafael, J.A., Chamberlain, J.S. and Campbell, K.P. (1995) Identification of alpha-syntrophin binding to syntrophin triplet, dystrophin, and utrophin. J. Biol. Chem., 270, 4975-4978
11. Ehmsen, J., Poon, E. and Davies, K. (2002) The dystrophin-associated protein complex. J. Cell Sci., 115, 2801-2803
12. Johnson, E.K., Li, B., Yoon, J.H., Flanigan, K.M., Martin, P.T., Ervasti, J. and Montanaro, F. (2013) Identification of newdystroglycan complexes in skeletal muscle. PLoS One, 8, 15-17
13. Strakova, J., Dean, J.D., Sharpe, K.M., Meyers, T.A., Odom, G.L. and Townsend, D. (2014) Dystrobrevin increases dystrophin's binding to the dystrophin-glycoprotein complex and provides protection during cardiac stress. J. Mol. Cell. Cardiol., 76, 106-115
14. Barton-Davis, E.R., Cordier, L., Shoturma, D.I., Leland, S.E. and Sweeney, H.L. (1999) Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J. Clin. Invest., 104, 375-381
15. Malik, V., Rodino-Klapac, L.R., Viollet, L. and Mendell, J.R. (2010) Aminoglycoside-induced mutation suppression (stop codon readthrough) as a therapeutic strategy for Duchenne muscular dystrophy. Ther. Adv. Neurol. Disord., 3, 379-389
16. Goyenvalle, A., Vulin, A., Fougerousse, F., Leturcq, F., Kaplan, J.-C., Garcia, L. and Danos, O. (2004) Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science, 306, 1796-1799
17. Lu, Q.L., Rabinowitz, A., Chen, Y.C., Yokota, T., Yin, H., Alter, J., Jadoon, A., Bou-Gharios, G. and Partridge, T. (2005) Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc. Natl. Acad. Sci. U. S. A., 102, 198-203
18. Yokota, T., Lu, Q.L., Partridge, T., Kobayashi, M., Nakamura, A., Takeda, S. and Hoffman, E. (2009) Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann. Neurol., 65, 667-676
19. Yokota, T., Nakamura, A., Nagata, T., Saito, T., Kobayashi, M., Aoki, Y., Echigoya, Y., Partridge, T., Hoffman, E.P. and Takeda, S. (2012) Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs. Nucleic Acid Ther., 22, 306-315
20. Goyenvalle, A., Griffith, G., Babbs, A., Andaloussi, S.E., Ezzat, K., Avril, A., Dugovic, B., Chaussenot, R., Ferry, A., Voit, T. et al. (2015) Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers. Nat. Med., 21, 270-275
21. Gregorevic, P., Blankinship, M.J., Allen, J.M., Crawford, R.W., Miller, D.G., Russell, D.W. and Chamberlain, J.S. (2004) Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat. Med., 10, 828-834
22. Gregorevic, P., Blankinship, M.J., Allen, J.M. and Chamberlain, J.S. (2008) Systemic microdystrophin gene delivery improves skeletal muscle structure and function in old dystrophic mdx mice. Mol. Ther., 16, 657-664
23. Rodino-Klapac, L.R., Janssen, P.M.L., Shontz, K.M., Canan, B., Montgomery, C.L., Griffin, D., Heller, K., Schmelzer, L., Handy, C., Clark, K.R. et al. (2013) Micro-dystrophin and follistatin co-delivery restores muscle function in aged DMD model. Hum. Mol. Genet., 22, 4929-4937
24. Love, D.R., Forrest, S.M., Smith, T.J., England, S., Flint, T. and Davies, K.E. (1989) Molecular analysis of Duchenne and Becker muscular dystrophy. Br. Med. Bull., 45, 659-680
25. Blake, D.J., Weir, A., Newey, S.E. and Davies, K.E. (2002) Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol. Rev., 82, 291-329
26. Khurana, T.S., Watkins, S.C., Chafey, P., Chelly, J., Tomé, F.M., Fardeau, M., Kaplan, J.C. and Kunkel, L.M. (1991) Immunolocalization and developmental expression of dystrophin related protein in skeletal muscle. Neuromuscul. Disord., 1, 185-194
27. Ohlendieck, K., Ervasti, J.M., Matsumura, K., Kahl, S.D., Leveille, C.J. and Campbell, K.P. (1991) Dystrophin-related protein is localized to neuromuscular junctions of adult skeletal muscle. Neuron, 7, 499-508
28. Belanto, J.J., Mader, T.L., Eckhoff, M.D., Strandjord, D.M., Banks, G.B., Gardner, M.K., Lowe, D.A. and Ervasti, J.M. (2014) Microtubule binding distinguishes dystrophin from utrophin. Proc. Natl. Acad. Sci. U. S. A., 111, 5723-5728
29. Peters, M.F., Sadoulet-Puccio, H.M., Grady, R.M., Kramarcy, N.R., Kunkel, L.M., Sanes, J.R., Sealock, R. and Froehner, S. C. (1998) Differential membrane localization and intermolecular associations of a-dystrobrevin isoforms in skeletal muscle. J. Cell Biol., 142, 1269-1278
30. Ishikawa-Sakurai, M., Yoshida, M., Imamura, M., Davies, K.E. and Ozawa, E. (2004) ZZ domain is essentially required for the physiological binding of dystrophin and utrophin to beta-dystroglycan. Hum. Mol. Genet., 13, 693-702
31. Winder, S.J., Hemmings, L., Maciver, S.K., Bolton, S.J., Tinsley, J.M., Davies, K.E., Critchley, D.R. and Kendrick-Jones, J. (1995) Utrophin actin binding domain: analysis of actin binding and cellular targeting. J. Cell Sci., 108, 63-71
32. Perkins, K.J. and Davies, K.E. (2002) The role of utrophin in the potential therapy of Duchenne muscular dystrophy. Neuromuscul. Disord., 12, 17-20
33. Mizuno, Y., Nonaka, I., Hirai, S. and Ozawa, E. (1993) Reciprocal expression of dystrophin and utrophin in muscles of Duchenne muscular dystrophy patients, female DMD-carriers and control subjects. J. Neurol. Sci., 119, 43-52
34. De la Porte, S., Morin, S. and Koenig, J. (1999) Characteristics of skeletal muscle in mdx mutant mice. Int. Rev. Cytol., 191, 99-148
35. Kleopa, K.A., Drousiotou, A., Mavrikiou, E., Ormiston, A. and Kyriakides, T. (2006) Naturally occurring utrophin correlates with disease severity in Duchenne muscular dystrophy. Hum. Mol. Genet., 15, 1623-1628
36. Tinsley, J.M., Potter, A.C., Phelps, S.R., Fisher, R., Trickett, J.I. and Davies, K.E. (1996) Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene. Nature, 384, 349-353
37. Rafael, J.A., Tinsley, J.M., Potter, A.C., Deconinck, A.E. and Davies, K.E. (1998) Skeletal muscle-specific expression of a utrophin transgene rescues utrophin-dystrophin deficient mice. Nat. Genet., 19, 79-82
38. Perkins, K.J., Burton, E.A. and Davies, K.E. (2001) The role of basal and myogenic factors in the transcriptional activation of utrophin promoter A: implications for therapeutic upregulation in Duchenne muscular dystrophy. Nucleic Acids Res., 29, 4843-4850
39. Squire, S., Raymackers, J.M., Vandebrouck, C., Potter, A., Tinsley, J., Fisher, R., Gillis, J.M. and Davies, K.E. (2002) Prevention of pathology in mdx mice by expression of utrophin: analysis using an inducible transgenic expression system. Hum. Mol. Genet., 11, 3333-3344
40. Krag, T.O.B., Bogdanovich, S., Jensen, C.J., Fischer, M.D., Hansen-Schwartz, J., Javazon, E.H., Flake, A.W., Edvinsson, L. and Khurana, T.S. (2004) Heregulin ameliorates the dystrophic phenotype in mdx mice. Proc. Natl. Acad. Sci. U. S. A., 101, 13856-13860
41. Tinsley, J., Robinson, N. and Davies, K.E. (2015) Safety, tolerability, and pharmacokinetics of SMT C1100, a 2-arylbenzoxazole utrophin modulator, following singleand multiple-dose administration to healthy male adult volunteers. J. Clin. Pharmacol., 10.1002/jcph.468
42. Khurana, T.S. and Davies, K.E. (2003) Pharmacological strategies for muscular dystrophy. Nat. Rev. Drug Discov., 2, 379-390
43. Moorwood, C., Lozynska, O., Suri, N., Napper, A.D., Diamond, S.L. and Khurana, T.S. (2011) Drug discovery for duchenne muscular dystrophy via utrophin promoter activation screening. PLoS One, 6, 1-11
44. Moorwood, C., Soni, N., Patel, G., Wilton, S.D. and Khurana, T.S. (2012) A cell-based high-throughput screening assay for posttranscriptional utrophin upregulation. J. Biomol. Screen., 18, 400-406
45. Gramolini, A.O. and Jasmin, B.J. (1999) Expression of the utrophin gene during myogenic differentiation. Nucleic Acids Res., 27, 3603-3609
46. Dennis, C.L., Tinsley, J.M., Deconinck, A.E. and Davies, K.E. (1996) Molecular and functional analysis of the utrophin promoter. Nucleic Acids Res., 24, 1646-1652
47. Gramolini, A.O., Dennis, C.L., Tinsley, J.M., Robertson, G.S., Cartaud, J., Davies, K.E. and Jasmin, B.J. (1997) Local transcriptional control of utrophin expression at the neuromuscular synapse. J. Biol. Chem., 272, 8117-8120
48. Chakkalakal, J.V., Stocksley, M.A., Harrison, M.-A., Angus, L. M., Deschenes-Furry, J., St-Pierre, S., Megeney, L.A., Chin, E. R., Michel, R.N. and Jasmin, B.J. (2003) Expression of utrophin A mRNA correlates with the oxidative capacity of skeletal muscle fiber types and is regulated by calcineurin/NFAT signaling. Proc. Natl. Acad. Sci. U. S. A., 100, 7791-7796
49. Angus, L.M., Chakkalakal, J.V., Méjat, A., Eibl, J.K., Bélanger, G., Megeney, L.A., Chin, E.R., Schaeffer, L., Michel, R.N. and Jasmin, B.J. (2005) Calcineurin-NFAT signaling, together with GABP and peroxisome PGC-1alpha, drives utrophin gene expression at the neuromuscular junction. Am. J. Physiol. Cell Physiol., 289, C908-C917
50. Luquet, S., Lopez-Soriano, J., Holst, D., Fredenrich, A., Melki, J., Rassoulzadegan, M. and Grimaldi, P.A. (2003) Peroxisome proliferator-activated receptor controls muscle development and oxidative capability. FASEB J., 17, 2299-2301
51. Wang, Y.X., Zhang, C.L., Yu, R.T., Cho, H.K., Nelson, M.C., Bayuga-Ocampo, C.R., Ham, J., Kang, H. and Evans, R.M. (2004) Regulation of muscle fiber type and running endurance by PPARdelta. PLoS Biol., 2, 1532-1539
52. Ehrenborg, E.W.A. and Krook, A. (2009) Regulation of skeletal muscle physiology and metabolism by peroxisome proliferator-activated receptor. Pharmacol. Rev., 61, 373-393
53. Ljubicic, V., Miura, P., Burt, M., Boudreault, L., Khogali, S., Lunde, J.A., Renaud, J.M. and Jasmin, B.J. (2011) Chronic AMPK activation evokes the slow, oxidative myogenic program and triggers beneficial adaptations in mdx mouse skeletal muscle. Hum. Mol. Genet., 20, 3478-3493
54. Lin, J., Wu, H., Tarr, P.T., Zhang, C.Y., Wu, Z., Boss, O., Michael, L.F., Puigserver, P., Isotani, E., Olson, E.N. et al. (2002) Transcriptional co-activator PGC-1alpha drives the formation of slow-twitch muscle fibres. Nature, 418, 797-801
55. Lira, V.A., Benton, C.R., Zhen, Y. and Bonen, A. (2010) PGC-1α regulation by exercise training and its influences on muscle function and insulin sensitivity. Am. J. Physiol. Endocrinol. Metab., 299, E145-E161
56. Chalkiadaki, A., Igarashi, M., Nasamu, A.S., Knezevic, J. and Guarente, L. (2014) Muscle-specific SIRT1 gain-of-function increases slow-twitch fibers and ameliorates pathophysiology in a mouse model of Duchenne muscular dystrophy. PLoS Genet., 10, 1-12
57. Perkins, K.J., Basu, U., Budak, M.T., Ketterer, C., Baby, S.M., Lozynska, O., Lunde, J.A., Jasmin, B.J., Rubinstein, N.A. and Khurana, T.S. (2007) Ets-2 Repressor factor silences extrasynaptic utrophin by N-Box-mediated repression in skeletal muscle. Mol. Biol. Cell, 18, 2991-3001
58. Blanchet, E., Annicotte, J., Lagarrigue, S., Aguilar, V., Clapé, C., Chavey, C., Fritz, V., Casas, F., Apparailly, F., Auwerx, J. et al. (2011) E2F transcription factor-1 regulates oxidative metabolism. Nat. Cell Biol., 13, 1-16
59. Al-Rewashdy, H., Ljubicic, V., Lin, W., Renaud, J.-M. and Jasmin, B.J. (2014) Utrophin A is essential in mediating the functional adaptations of mdx mouse muscle following chronic AMPK activation. Hum. Mol. Genet., 24, 1243-1255
60. Miura, P., Chakkalakal, J.V., Boudreault, L., Bélanger, G., Hébert, R.L., Renaud, J.M. and Jasmin, B.J. (2009) Pharmacological activation of PPARß/d stimulates utrophin A expression in skeletal muscle fibers and restores sarcolemmal integrity in mature mdx mice. Hum. Mol. Genet., 18, 4640-4649
61. Ljubicic, V., Burt, M., Lunde, J.A. and Jasmin, B.J. (2014) Resveratrol induces expression of the slow, oxidative phenotype in mdx mouse muscle together with enhanced activity of the SIRT1-PGC-1α axis. Am. J. Physiol. Cell Physiol., 307, C66-C82
62. Winder, W.W., Holmes, B.F., Rubink, D.S., Jensen, E.B., Chen, M. and Holloszy, J.O. (2000) Activation of AMP-activated protein kinase increases mitochondrial enzymes in skeletal muscle. J. Appl. Physiol., 88, 2219-2226
63. Jørgensen, S.B., Treebak, J.T., Viollet, B., Schjerling, P., Vaulont, S., Wojtaszewski, J.F.P. and Richter, E.A. (2007) Role of AMPKalpha2 in basal, training-, and AICAR-induced GLUT4, hexokinase II, and mitochondrial protein expression in mouse muscle. Am. J. Physiol. Endocrinol. Metab., 292, E331-E339
64. Boon, H., Bosselaar, M., Praet, S.F.E., Blaak, E.E., Saris, W.H. M., Wagenmakers, A.J.M., McGee, S.L., Tack, C.J., Smits, P., Hargreaves, M. et al. (2008) Intravenous AICAR administration reduces hepatic glucose output and inhibits whole body lipolysis in type 2 diabetic patients. Diabetologia, 51, 1893-1900
65. Riserus, U., Sprecher, D., Johnson, T., Olson, E., Hirschberg, S., Liu, A., Fang, Z., Hegde, P., Richards, D., Sarov-Blat, L. et al. (2008) Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes, 57, 332-339
66. Olson, E.J., Pearce, G.L., Jones, N.P. and Sprecher, D.L. (2012) Lipid effects of peroxisome proliferator-activated receptordelta agonist GW501516 in subjects with low high-density lipoprotein cholesterol: Characteristics of metabolic syndrome. Arterioscler. Thromb. Vasc. Biol., 32, 2289-2294
67. Ljubicic, V. and Jasmin, B.J. (2015) Metformin increases peroxisome proliferator-activated receptor γ Co-activator-1α and utrophin A expression in dystrophic skeletal muscle. Muscle Nerve, 52, 139-142
68. Chakkalakal, J.V., Miura, P., Bélanger, G., Michel, R.N. and Jasmin, B.J. (2008) Modulation of utrophin A mRNA stability in fast versus slow muscles via an AU-rich element and calcineurin signaling. Nucleic Acids Res., 36, 826-838
69. Gramolini, A.O., Bélangera, G. and Jasmin, B.J. (2001) Distinct regions in the 3' untranslated region are responsible for targeting and stabilizing utrophin transcripts in skeletal muscle cells. J. Cell Biol., 154, 1173-1183
70. Miura, P., Andrews, M., Holcik, M. and Jasmin, B.J. (2008) IRES-mediated translation of utrophin A is enhanced by glucocorticoid treatment in skeletal muscle cells. PLoS One, 3, e2309
71. Miura, P., Coriati, A., Bélanger, G., de Repentigny, Y., Lee, J., Kothary, R., Holcik, M. and Jasmin, B.J. (2010) The utrophin A 5'-UTR drives cap-independent translation exclusively in skeletal muscles of transgenic mice and interacts with eEF1A2. Hum. Mol. Genet., 19, 1211-1220
72. Moorwood, C. and Khurana, T.S. (2013) Duchenne muscular dystrophy drug discovery-the application of utrophin promoter activation screening. Expert Opin. Drug Discov., 8, 569-581
73. Miura, P., Thompson, J., Chakkalakal, J.V., Holcik, M. and Jasmin, B.J. (2005) The utrophin A 5'-untranslated region confers internal ribosome entry site-mediated translational control during regeneration of skeletal muscle fibers. J. Biol. Chem., 280, 32997-33005
74. Bakheet, T., Williams, B.R.G. and Khabar, K.S.A. (2003) ARED 2.0: an update of AU-rich element mRNA database. Nucleic Acids Res., 31, 421-423
75. Apponi, L.H., Corbett, A.H. and Pavlath, G.K. (2011) RNAbinding proteins and gene regulation in myogenesis. Trends Pharmacol. Sci., 32, 652-658
76. Basu, U., Lozynska, O., Moorwood, C., Patel, G., Wilton, S.D. and Khurana, T.S. (2011) Translational regulation of utrophin by miRNAs. PLoS One, 6, e29376
77. Amirouche, A., Tadesse, H., Lunde, J.A., Bélanger, G., Côté, J. and Jasmin, B.J. (2013) Activation of p38 signaling increases utrophin A expression in skeletal muscle via the RNAbinding protein KSRP and inhibition of AU-rich elementmediated mRNA decay: implications for novel DMD therapeutics. Hum. Mol. Genet., 22, 3093-3111
78. Zbinden-Foncea, H., Raymackers, J.M., Deldicque, L., Renard, P. and Francaux, M. (2012) TLR2 and TLR4 activate p38 MAPK and JNK during endurance exercise in skeletal muscle. Med. Sci. Sports Exerc., 44, 1463-1472
79. Gray, E., Mulloy, B. and Barrowcliffe, T.W. (2008) Heparin and low-molecular-weight heparin. Thromb. Haemost., 99, 807-818
80. Tinsley, J.M., Fairclough, R.J., Storer, R., Wilkes, F.J., Potter, A. C., Squire, S.E., Powell, D.S., Cozzoli, A., Capogrosso, R.F., Lambert, A. et al. (2011) Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse. PLoS One, 6, e19189
81. Jahnke, V.E., Van Der Meulen, J.H., Johnston, H.K., Ghimbovschi, S., Partridge, T., Hoffman, E.P. and Nagaraju, K. (2012) Metabolic remodeling agents show beneficial effects in the dystrophin-deficient mdx mouse model. Skelet. Muscle, 2, 16
82. Gramolini, A.O., Bélanger, G., Thompson, J.M., Chakkalakal, J.V. and Jasmin, B.J. (2001) Increased expression of utrophin in a slow versus a fast muscle involves posttranscriptional events. Am. J. Physiol. Cell Physiol., 281, C1300-C1309
83. Briguet, A., Courdier-Fruh, I., Foster, M., Meier, T. and Magyar, J.P. (2004) Histological parameters for the quantitative assessment of muscular dystrophy in the mdx-mouse. Neuromuscul. Disord., 14, 675-682
84. Torres, L.F. and Duchen, L.W. (1987) The mutant mdx: inherited myopathy in the mouse. Morphological studies of nerves, muscles and end-plates. Brain, 110, 269-299
85. Machida, K., Cheng, K.T.H., Sung, V.M.H., Levine, A.M., Foung, S. and Lai, M.M.C. (2006) Hepatitis C virus induces Toll-like receptor 4 expression, leading to enhanced production of beta interferon and interleukin-6. J. Virol., 80, 866-874
86. Serrano, A.L., Baeza-Raja, B., Perdiguero, E., Jardi, M. and Munoz-Canoves, P. (2008) Interleukin-6 is an essential regulator of satellite cell-mediated skeletal muscle hypertrophy. Cell Metab., 7, 33-44
87. Pillon, N.J., Bilan, P.J., Fink, L.N. and Klip, A. (2013) Cross-talk between skeletal muscle and immune cells: muscle-derived mediators and metabolic implications. Am J Physiol Endocrinol Metab, 304, E453-E465
88. Gordon, B.S., Delgado, D.C. and Kostek, M.C. (2013) Resveratrol decreases inflammation and increases utrophin gene expression in the mdx mouse model of Duchenne muscular dystrophy. Clin. Nutr., 32, 104-111
89. Straub, V., Rafael, J.A., Chamberlain, J.S. and Campbell, K.P. (1997) Animal models for muscular dystrophy show different patterns of sarcolemmal disruption. J. Cell Biol., 139, 375-385
90. Petrof, B.J., Shrager, J.B., Stedman, H.H., Kelly, A.M. and Sweeney, H.L. (1993) Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc. Natl. Acad. Sci. U. S. A., 90, 3710-3714
91. Bogdanovich, S., Krag, T.O.B., Barton, E.R., Morris, L.D., Whittemore, L.A., Ahima, R.S. and Khurana, T.S. (2002) Functional improvement of dystrophic muscle by myostatin blockade. Nature, 420, 418-421
92. Merrill, G.F., Kurth, E.J., Hardie, D.G. and Winder, W.W. (1997) AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle. Am J Physiol, 273, E1107-E1112
93. Holmes, B.F., Kurth-Kraczek, E.J. and Winder, W.W. (1999) Chronic activation of 5'-AMP-activated protein kinase increases GLUT-4, hexokinase, and glycogen in muscle. J. Appl. Physiol., 87, 1990-1995
94. Irrcher, I., Ljubicic, V., Kirwan, A.F. and Hood, D.A. (2008) AMP-activated protein kinase-regulated activation of the PGC-1α promoter in skeletal muscle cells. PLoS One, 3, e3614
95. Buhl, E.S., Jessen, N., Pold, R., Ledet, T., Flyvbjerg, A., Pedersen, S.B., Pedersen, O., Schmitz, O. and Lund, S. (2002) Long-term AICAR administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome. Diabetes, 51, 2199-2206
96. Bamford, J.A., Lopaschuk, G.D., MacLean, I.M., Reinhart, M. L., Dixon, W.T. and Putman, C.T. (2003) Effects of chronic AICAR administration on the metabolic and contractile phenotypes of rat slow-and fast-twitch skeletal muscles. Can. J. Physiol. Pharmacol., 81, 1072-1082
97. Drake, J.C., Alway, S.E., Hollander, J.M. and Williamson, D.L. (2010) AICAR treatment for 14 days normalizes obesity-induced dysregulation of TORC1 signaling and translational capacity in fasted skeletal muscle. Am. J. Physiol. Regul. Integr. Comp. Physiol., 299, R1546-R1554
98. Fillmore, N., Jacobs, D.L., Mills, D.B., Winder, W.W. and Hancock, C.R. (2010) Chronic AMP-activated protein kinase activation and a high-fat diet have an additive effect on mitochondria in rat skeletal muscle. J. Appl. Physiol., 109, 511-520
99. Leick, L., Fentz, J., Bienso, R.S., Knudsen, J.G., Jeppesen, J., Kiens, B., Wojtaszewski, J.F.P. and Pilegaard, H. (2010) PGC-1 is required for AICAR-induced expression of GLUT4 and mitochondrial proteins in mouse skeletal muscle. AJP Endocrinol. Metab., 299, E456-E465
100. Liao, P., Georgakopoulos, D., Kovacs, A., Zheng, M., Lerner, D., Pu, H., Saffitz, J., Chien, K., Xiao, R.P., Kass, D.A. et al. (2001) The in vivo role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathy. PNAS, 98, 12283-12288
101. Liang, Q. and Molkentin, J.D. (2003) Redefining the roles of p38 and JNK signaling in cardiac hypertrophy: Dichotomy between cultured myocytes and animal models. J. Mol. Cell. Cardiol., 35, 1385-1394
102. Clerk, A. and Sugden, P.H. (2006) Inflame my heart (by p38-MAPK). Circ. Res., 99, 455-458
103. Streicher, J.M., Ren, S., Herschman, H. and Wang, Y. (2010) MAPK-activated protein kinase-2 in cardiac hypertrophy and cyclooxygenase-2 regulation in heart. Circ. Res., 106, 1434-1443
104. Irrcher, I., Adhihetty, P.J., Sheehan, T., Joseph, A.M. and Hood, D.A. (2003) PPARgamma coactivator-1alpha expression during thyroid hormone-and contractile activityinduced mitochondrial adaptations. Am. J. Physiol. Cell Physiol., 284, C1669-C1677
105. Suwa, M., Nakano, H. and Kumagai, S. (2003) Effects of chronic AICAR treatment on fiber composition, enzyme activity, UCP3, and PGC-1 in rat muscles. J. Appl. Physiol., 95, 960-968
106. Pasquini, F., Guerin, C., Blake, D., Davies, K., Karpati, G. and Holland, P. (1995) The effect of glucocorticoids on the accumulation of utrophin by cultured normal and dystrophic human skeletal muscle satellite cells. Neuromuscul. Disord., 5, 105-114
107. Weir, A.P., Burton, E.A., Harrod, G. and Davies, K.E. (2002) Aand B-utrophin have different expression patterns and are differentially up-regulated in mdx muscle. J. Biol. Chem., 277, 45285-45290
108. Briata, P., Forcales, S.V., Ponassi, M., Corte, G., Chen, C.Y., Karin, M., Puri, P.L. and Gherzi, R. (2005) p38-Dependent phosphorylation of the mRNA decay-promoting factor KSRP controls the stability of select myogenic transcripts. Mol. Cell, 20, 891-903
109. Senn, J.J. (2006) Toll-like receptor-2 is essential for the development of palmitate-induced insulin resistance in myotubes. J. Biol. Chem., 281, 26865-26875
110. Reyna, S.M., Ghosh, S., Tantiwong, P., Meka, R.C.S., Eagan, P., Jenkinson, C.P., Cersosimo, E., Defronzo, R.A., Coletta, D.K., Sriwijitkamol, A. et al. (2008) Elevated toll-like receptor 4 expression and signaling in muscle from insulin-resistant subjects. Diabetes, 57, 2595-2602
111. Rawat, R., Cohen, T.V., Ampong, B., Francia, D., Henriques-Pons, A., Hoffman, E.P. and Nagaraju, K. (2010) Inflammasome up-regulation and activation in dysferlin-deficient skeletal muscle. Am. J. Pathol., 176, 2891-2900
112. Henriques-Pons, A., Yu, Q., Rayavarapu, S., Cohen, T.V., Ampong, B., Cha, H.J., Jahnke, V., Van der meulen, J., Wang, D., Jiang, W. et al. (2014) Role of toll-like receptors in the pathogenesis of dystrophin-deficient skeletal and heart muscle. Hum. Mol. Genet., 23, 2604-2617
113. Giordano, C., Mojumdar, K., Liang, F., Lemaire, C., Li, T., Richardson, J., Divangahi, M., Qureshi, S. and Petrof, B.J. (2014) Toll-like receptor 4 ablation in mdx mice reveals innate immunity as a therapeutic target in Duchenne muscular dystrophy. Hum. Mol. Genet., 24, 2147-2162
114. Reyes, N.L., Banks, G.B., Tsang, M., Margineantu, D., Gu, H., Djukovic, D., Chan, J., Torres, M., Liggitt, H.D., Hirenallur-S, D.K. et al. (2015) Fnip1 regulates skeletal muscle fiber type specification, fatigue resistance, and susceptibility to muscular dystrophy. Proc. Natl. Acad. Sci., 112, 424-429
115. Marusich, M.F., Robinson, B.H., Taanman, J.W., Kim, S.J., Schillace, R., Smith, J.L. and Capaldi, R.A. (1997) Expression of mtDNA and nDNA encoded respiratory chain proteins in chemically and genetically-derived Rho0 human fibroblasts: a comparison of subunit proteins in normal fibroblasts treated with ethidium bromide and fibroblasts from a patient with mtDNA depletion syndrome. Biochim. Biophys. Acta-Mol. Basis Dis., 1362, 145-159
116. Wang, L., Liu, Z., Dong, Z., Pan, J. and Ma, X. (2014) Azurocidin-induced inhibition of oxygen metabolism in mitochondria is antagonized by heparin. Exp. Ther. Med., 8, 1473-1478
117. Corton, J.M., Gillespie, J.G., Hawley, S.A. and Hardie, D.G. (1995) 5-Aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? Eur. J. Biochem., 229, 558-565
118. Tinsley, J., Deconinck, N., Fisher, R., Kahn, D., Phelps, S., Gillis, J.M. and Davies, K. (1998) Expression of full-length utrophin prevents muscular dystrophy in mdx mice. Nat. Med., 4, 1441-1444
119. Ashburn, T.T. and Thor, K.B. (2004) Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov., 3, 673-683
120. Babraj, J.A., Mustard, K., Sutherland, C., Towler, M.C., Chen, S., Smith, K., Green, K., Leese, G., Hardie, D.G., Rennie, M.J. et al. (2009) Blunting of AICAR-induced human skeletal muscle glucose uptake in type 2 diabetes is dependent on age rather than diabetic status. Am. J. Physiol. Endocrinol. Metab., 296, E1042-E1048
121. Suwa, M., Egashira, T., Nakano, H., Sasaki, H. and Kumagai, S. (2006) Metformin increases the PGC-1alpha protein and oxidative enzyme activities possibly via AMPK phosphorylation in skeletal muscle in vivo. J. Appl. Physiol., 101, 1685-1692